content_top
43 companies, 1 interpreter! Insight, foresight
and recommendation 

Caladrius Biosciences (CLBS)

3.90
-0.09
(-2.36%)
Sep 11, 3:59PM EDT
content_middle

Caladrius (CLBS) the former NeoStem engages in the development of proprietary cell therapy products. It is involved in the manufacture of cell therapy-based products, product and process development, cell and tissue processing, regulatory support, storage, distribution and delivery, and consulting services. The company also provides contract development and manufacturing services to clients advancing regenerative medicine product candidates in the regenerative medicine industry; adult stem cell collection and storage services; and therapy development utilizing T-cells for autoimmune and inflammatory conditions, including graft vs. host disease, type 1 diabetes, steroid resistant asthma, lupus, multiple sclerosis, and solid organ transplant rejection. In addition, it engages in developing AMR-001, a chemotactic hematopoietic stem cell product comprised of autologous bone marrow derived CD34+/CXCR4+ cells, which is in P2 study for the treatment of damaged heart muscle; and researching and developing new therapies based on Very Small Embryonic-Like technology. It has a collaboration agreement with Becton-Dickinson.  Founded as NeoStem in 1980, CLBS is headquartered in Basking Ridge, NJ.

Previous Close: 
3.99
Open: 
3.95
Bid: 
3.70
Ask: 
4.07
1yr Target Price: 
5.00
Day's Range: 
3.85 - 4.08
52wk Range: 
2.65 - 7.79
Volume: 
39033
Average Daily Volume: 
30170
Market Capitalization: 
N/A
Trailing Annual Dividend Yield: 
N/A
Shares Outstanding: 
N/AM
content_right